Initial Statement of Beneficial Ownership (3)
February 19 2013 - 11:10AM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Zukiwski Alexander A
|
2. Date of Event Requiring Statement (MM/DD/YYYY)
1/25/2013
|
3. Issuer Name
and
Ticker or Trading Symbol
Arno Therapeutics, Inc [ARNI]
|
(Last)
(First)
(Middle)
200 ROUTE 31 NORTH, SUITE 104
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___
X
___ Officer (give title below)
_____ Other (specify below)
VP & Chief Medical Officer /
|
(Street)
FLEMINGTON, NJ 08822
(City)
(State)
(Zip)
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security
(Instr. 4)
|
2. Amount of Securities Beneficially Owned
(Instr. 4)
|
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
|
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 4)
|
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
|
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
|
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (right to buy)
|
(1)
|
6/22/2021
|
Common Stock
|
875000
|
$.30
|
D
|
|
Stock Option (right to buy)
|
(2)
|
6/22/2021
|
Common Stock
|
445891
|
$.30
|
D
|
|
Stock Option (right to buy)
|
(3)
|
1/14/2023
|
Common Stock
|
292500
|
$.30
|
D
|
|
Stock Option (right to buy)
|
(4)
|
1/14/2023
|
Common Stock
|
97500
|
$.30
|
D
|
|
8% Senior Convertible Debentures
|
11/26/2012
|
11/26/2015
|
Common Stock
|
500000
|
$.30
|
D
|
|
Series A Warrants (right to buy)
|
11/26/2012
|
11/26/2017
|
Common Stock
|
500000
|
$.50
|
D
|
|
Series B Warrants (right to buy)
|
11/26/2012
|
5/26/2014
|
Common Stock
|
500000
|
$.30
|
D
|
|
Explanation of Responses:
|
(
1)
|
25% vested on 6/22/12 and thereafter will vest in 24 equal monthly installments.
|
(
2)
|
On 6/22/2011, the Reporting Person was granted an option to purchase up to 875,000 shares of common stock of the Issuer. Up to 1/3 of the shares subject to the option may vest annually (or a pro rata portion thereof for a period of less than a full year) based on the achievement of certain performance milestones as determined by the Board of Directors (the 'Board') of the Issuer. On 1/17/2012, the Board determined that options for the prorated period ending 12/31/2011 would vest in the maximum potential amount of 154,224 shares. On 1/14/2013, the Board determined that options for the period ending 12/31/2012 would vest in the maximum potential amount of 291,667 shares.
|
(
3)
|
1/3 vested on 1/14/13 and thereafter will vest in 24 equal monthly installments, commencing 1/31/13.
|
(
4)
|
On 1/14/2013, the Reporting Person was granted an option to purchase up to 292,500 shares of common stock of the Issuer. 1/3 of the shares subject to the option were immediately vested and up to 1/2 of the remaining shares subject to the option may vest annually, based on the achievement of certain performance milestones as determined by the Board.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Zukiwski Alexander A
200 ROUTE 31 NORTH
SUITE 104
FLEMINGTON, NJ 08822
|
|
|
VP & Chief Medical Officer
|
|
Signatures
|
/s/ Alexander A. Zukiwski, M.D.
|
|
2/14/2013
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 5(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jul 2023 to Jul 2024